Alzamend Neuro is trading at $1.18, down -5.60%, amid broad market weakness.
- No October 22 company-specific announcement explaining the decline appeared in the company’s news feed; its latest listed release was September 16.
- The Nasdaq fell more than 0.5% alongside risk-off sentiment, rising geopolitical tensions and oil prices, and uncertainty about costly AI investment.
- No trading-volume evidence available here confirms unusually heavy activity; the supplied price context reports a live move.